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Abstract: The first members of a new family of heterocarbobicyclic nucleoside 
analogues have been synthesized from the cis/trans mixture of (4-amino-5,6-dihydro-
4H-cyclopenta[b]thiophen-6-yl)methanols cis/trans-7. The separation of cis and trans 
intermediates during preparation of the 6-chloropurine derivatives allowed separate  
preparation of the purine heterocarbanucleosides cis-10 and trans-11, from which cis-
(12-14) and trans-(16-18) were obtained by replacement of the 6-chloro substituent with 
amino, hydroxy and cyclopropylamino groups. Additionally, the 6-phenyl-purinyl 
analogues cis-15 and trans-19 were prepared from cis-10 and trans-11 using Suzuki-
Miyaura methodology. 
Introduction 
The development of new antiviral drugs is a dynamic process driven by the 
identification of new molecular targets and the emergence of problems associated with 
drugs in current clinical use (resistance, toxicity, etc.).[1] In recent decades, many 
research programs have sought non-toxic antiviral drugs that act by selective inhibition 
of kinases or polymerases.[2] Among the most extensively and intensively studied 
compounds are the nucleoside analogues, which become active when acted upon by 
kinases after entry into a target cell. A number of these prodrugs have been found to 







The many structural modifications that have been made to natural nucleosides in the 
search for desired biological properties include the introduction of a double bond 
between positions 2’ and 3’ of the sugar ring. The seminal work of Balzarini et al.[4] 
showed that when the parent compound is a pyrimidine nucleoside the resulting 
cytosine and thymidine analogues (respectively d4C (1) and d4T (2); see Figure 1) are 
active against human immunodeficiency virus (HIV), and d4T is still in clinical use 
under the commercial name Stavudine®.[5] The antiviral activity of these compounds is 
thought to be related to the conformational restriction imposed on the pseudosugar 
moiety by its double bond,[6] which also increases the lipophilicity of the molecule and 
thereby facilitate its access to the central nervous system, a major reservoir of the HIV 
virus.[7] 
In carbanucleosides (CNs),[8] the D-ribose moiety of the natural nucleosides is 
replaced by an aliphatic or aromatic carbocycle. CNs include the well-known anti-HIV 
agents carbovir (3)[9] and abacavir (4, marketed as Ziagen®);[10] the purine derivative 
BMS-200475 (5),[11] which is active against hepatitis B virus (HBV); and the 
pyrimidine derivative carba-BVDU (6), which is active in vitro against herpes simplex 
virus 1 (HSV-1) (Figure 2).[12] Once in a cell, they are active for longer than analogues 
with the endocyclic oxygen of natural nucleosides because they resist the 
phosphorylases and hydrolases that cleave the glycoside bonds of the latter. 
Furthermore, replacement of the endocyclic furanose oxygen by a methylene group 























In previous papers our research group reported the synthesis of abacavir analogues 
in which a purine or pyrimidine base was linked to an indane system.[13] Some of these 
compounds showed considerable cytostatic activity against human T lymphoblastic 
leukaemia cell lines (Molt4/C8 and CEM/0) and murine leukaemia cells (L1210/0),[14] 
and many of the active purine derivatives featured an oxo or amino group at position 6 
that would allow hydrogen bonding between the nucleobase and the polymerases and 
other enzymes involved in nucleic acid metabolism.[15]  
In the search for ways of increasing the lipophilicity and polar interactions of the 
pseudosugar while maintaining the rigidity of this moiety, our group has now begun to 
explore a new class of analogues in which the aromatic ring of the indane system has 
been replaced by a heterocyclic aromatic ring system.[16] The results have been 
encouraging: for example, preliminary biological assays of purinylmethyl derivatives of 
2-benzylcyclopenta[c]pyrazoles have found them to possess high activity against 
varicella zoster virus and cytomegalovirus at subcytotoxic concentrations,[17] and 
derivatives of 1-methylcyclopenta[c]pyrazoles have cytostatic activity.[18] We are 
currently exploring the case in which the pseudosugar is cyclopenta[b]thiopene; in the 
work reported here, we examined the dependence of the biological activity of some 
members of this family on the stereochemistry of the pseudosugar-nucleobase linkage. 
CNs are generally prepared either by constructing the nucleobase on the amino 
group of a suitable aminoalcohol,[19] or by direct coupling of the heterocyclic base with 
an appropriately functionalized carbocyclic system[16a-b,17] (e.g. by means of the 
Mitsunobu reaction).[13c,14a] In this work we chose the former approach not only because 
it allows divergent synthesis of multiple CNs from a single pseudosugar intermediate, 
but also because it would hopefully allow easy separation of stereoisomers with cis and 
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of the mixture of amino pseudosugar isomers cis/trans-7 had been found to afford only 
moderate combined yields). Our hopes in this respect were fulfilled, flash column 
chromatography of the heterocarbanucleoside precursors cis-8 and trans-9 (Scheme 1) 
was accomplished more eficiently (96%). These CNs have been synthesized in its 
racemic form, so the resolution of the enantiomers was planned for a later work, once 
the biological activities of the racemic mixtures were known. 
 
Results and discussion 
The aminoalcohol mixture cis/trans-7 was synthesized as before,[20] in 
spectroscopically determined 1:1 isomer ratio and 55% combined yield, by reduction of 
the corresponding hydroxyiminoester in refluxing THF with AlH3 that had been freshly 
prepared in quantitative yield from LiAlH4 and H2SO4.[21] Reaction of cis/trans-7 for 45 
hours with 5-amino-4,6-dichloropyrimidine and Et3N in refluxing nBuOH afforded a 
mixture of cis-8 and trans-9 in 41% and 36% yield, respectively (the combined yield of 
77% was less with shorter reaction times), and flash column chromatography of this 
mixture using 40:1 CHCl3/MeOH as eluent efficiently separated cis-8 from trans-9 (in 
addition, a small amount of starting material was recovered and traces of 5-amino-4-











Scheme 1. a) 5-Amino-4,6-dichloropyrimidine,nBuOH, Et3N, Δ. 
 
Treatment of cis-8 and trans-9 with triethyl orthoformiate under the classical 
conditions for synthesis of the 5-membered ring of purine[22] afforded the corresponding 
























In turn, these heterocarbanucleosides were directly converted into the corresponding 6-
amino, 6-cyclopropyl-amino and 6-hydroxy derivatives by reaction with the appropriate 
nucleophile: reaction with NH4OH in dioxane afforded cis-12 and trans-16 in 98% and 
85% yield, respectively; reaction with cyclopropylamine in refluxing EtOH, cis-13 
(88%) and trans-17 (73%); and reaction with 0.25 N NaOH in dioxane for 24 hours at 
















Scheme 2. (a) HC(OEt)3, 12 N HCl; (b) 14 M NH4OH, dioxane, Δ; (c) cPrNH2, EtOH, Δ; (d) 
0.25 N NaOH, dioxane, 50oC; (e) PhB(OH)3, K2CO3, Pd(PPh3)4. 
 
 
The relative configuration of the heterocarbanucleoside trans-18 was confirmed by 
means of x-ray crystallographic analysis of a single crystal obtained by recrystallization 











































































Figure 3. MERCURY projection (with 40% probability ellipsoids) of the molecular 
structure of trans-18 (the atomic numbering is arbitrary). 
 
In view of the high antineoplastic activities of certain 6-arylpurinyl nucleosides[15] 
and related acyclic nucleotide analogues[24] (including previous products of our 
group),[14a-b] we also synthesized the 6-arylpurinyl heterocarbanucleosides cis-15 and 
trans-19, using Hocek’s protocol[25] to achieve Suzuki-Miyaura cross-coupling[26] 
between 6-halopurines and boronic acids. Heating compounds cis-10 and trans-11 at 
100ºC with phenylboronic acid, tetrakis(triphenylphosphine)-palladium and potassium 
carbonate in dry toluene afforded the 6-phenyl derivatives cis-15 and trans-19 in good 





Melting points are uncorrected and were determined in a Reichert Kofler 
Thermopan or in capillary tubes in a Büchi 510 apparatus. Infrared spectra were 
recorded in a Perkin-Elmer 1640 FTIR spectrophotometer. 1H NMR spectra (300 MHz) 
and 13C NMR spectra (75 MHz) were recorded in a Bruker AMX 300 spectrometer 
using TMS as internal reference (chemical shifts in δ values, J in Hz). EI and FAB mass 
spectra were recorded on HP5988A and MICROMASS AUTOSPEC spectrometers, 
respectively. Microanalyses were performed in a Perkin-Elmer 240B elemental analyser 
by the Microanalysis Service of the University of Santiago. X-ray diffraction data were 
collected with an Enraf-Nonius CAD4 automatic diffractometer using the program 
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CAD4-EXPRESS. Most reactions were monitored by TLC on pre-coated silicagel 
plates (Merck 60 F254, 0.25 mm). Synthesized products were purified by flash column 
chromatography on silicagel (Merck 60, 230-240 mesh), and were crystallized if 
necessary. Solvents were dried by distillation prior to use. 
3.1.1 (±)-{cis-4-[(5-Amino-6-chloropyrimidin-4-yl)amino]-5,6-dihydro-4H-cyclo-
penta[b]thiophen-6-yl}methanol (8) and (±)-{trans-4-[(5-amino-6-chloropyrimidin-
4-yl)amino]-5,6-dihydro-4H-cyclopenta[b]thiophen-6-yl}methanol (9). 5-Amino-
4,6-dichloropyrimidine (1.04 g, 6.38 mmol) was added to a solution of the 
aminoalcohol mixture (±)-cis/trans-7 (0.6 g, 3.55 mmol) in dry n-butanol (60 mL) and 
triethylamine (4 mL). This mixture was refluxed under Ar for 45 hours, and once cool, 
the solvents were removed under reduced pressure. Chromatography of the solid residue 
on silica gel (60 g) using 40:1 CHCl3/MeOH as eluent afforded first (±)-cis-8 (0.43 g, 
41%) and then (±)-trans-9 (0.38 g, 36%).  
(±)-cis-8. An analytical sample was obtained by recrystallization from EtOAc. White 
solid. M.p. 197−198oC. Rf (20:1 CHCl3/MeOH) = 0.23. IR (KBr): ν = 3256, 2991, 
2934, 1582, 1505, 1482, 1425 and 1059 cm−1. 1H NMR (300 MHz, DMSO-d6) δ: 7.77 
(s, 1H, pyrimidine 2-H), 7.35 (d, 1H, J = 4.9 Hz, 2-H), 7.00 (d, 1H, J = 7.3 Hz, D2O 
exch., NH), 6.83 (d, 1H, J = 4.9 Hz, 3-H), 5.48-5.46 (m, 1H, 4-H), 5.09 (br s, 2H, D2O 
exch., NH2), 4.98−4.95 (m, 1H, D2O exch., OH), 3.69−3.59 (m, 1H, 6-H), 3.43−3.41 
(m, 1H, OCHH), 3.35−3.25 (m, 1H, OCHH), 3.02−2.97 (m, 1H, 5-H), 1.90−1.86 (m, 
1H, 5-H) ppm. 13C NMR (75 MHz, DMSO-d6) δ: 151.60 (pyrimidine C-6), 146.67 
(pyrimidine C-4), 146.02 (pyrimidine C-5), 145.84 (pyrimidine C-2), 137.43 (C-6a), 
129.46 (C-3), 123.88 (C-3a), 122.19 (C-2), 65.74 (CH2O), 51.81 (C-4), 43.51 (C-6), 
41.16 (C-5) ppm. EIMS, m/z (%): 297 (4) [M+1]+, 296 (11) [M+], 266 (3) [M+−CH2O], 
153 (100) [M+−C4H4ClN4], 135 (90) [M+−C4H6ClN4O], 125 (28), 121 (34). 
C12H13ClN4OS (296.05): calcd. C 48.56, H 4.42, Cl 11.95, N 18.88, S 10.80; found C 
48.41, H 4.51, Cl 12.03, N 18.72, S 11.02. 
(±)-trans-9. An analytical sample was obtained by recrystallization from EtOAc. White 
solid. M.p. 89−91oC. Rf (20:1 CHCl3/MeOH) = 0.17. IR (KBr): ν = 3442, 3346, 3245, 
2924, 1649, 1575, 1466, 1421 and 1089 cm−1. 1H NMR (300 MHz, DMSO-d6) δ: 7.78 
(s, 1H, pyrimidine 2-H), 7.35 (d, 1H, J = 5.1 Hz, 2-H), 7.01 (d, 1H, J = 7.2 Hz, D2O 
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exch., NH), 6.86 (d, 1H, J = 4.9 Hz, 3-H), 5.50−5.44 (m, 1H, 4-H), 5.07 (br s, 2H, D2O 
exch., NH2), 4.95−4.92 (m, 1H, D2O exch., OH), 3.59−3.50 (m, 1H, 6-H), 3.48−3.41 
(m, 2H, OCH2), 2.61−2.52 (m, 1H, 5-H), 2.39−2.31 (m, 1H, 5-H) ppm. 13C NMR (75 
MHz, DMSO-d6) δ: 151.54 (pyrimidine C-6), 146.85 (pyrimidine C-4), 146.60 
(pyrimidine C-5), 145.83 (pyrimidine C-2), 136.88 (C-6a), 129.49 (C-3), 123.91 (C-3a), 
122.39 (C-2), 65.47 (CH2O), 51.64 (C-4), 43.46 (C-6), 41.44 (C-5) ppm. EIMS, m/z 
(%): 296 (1) [M+], 278 (1) [M+−H2O], 153 (65) [M+−C4H4ClN4], 135 (100) 
[M+−C4H6ClN4O], 125 (38), 121 (60), 97 (31). C12H13ClN4OS (296.05): calcd. C 48.56, 
H 4.42, Cl 11.95, N 18.88, S 10.80; found C 49.02, H 4.38, Cl 12.14, N 18.67, S 11.05. 
3.1.2 (±)-[cis-4-(6-Chloro-9H-purin-9-yl)-5,6-dihydro-4H-cyclopenta[b]thiophen-6-
yl]methanol (10). A mixture of (±)-cis-8 (0.23 g, 0.78 mmol), triethyl orthoformiate 
(4.3 mL, 38.3 mmol), dioxane (10 mL) and 12 N HCl (0.27 mL) was stirred at room 
temperature for 22 hours. Once the reaction was judged to have terminated, the solvents 
were removed under reduced pressure. The resulting residue was dissolved in dioxane 
(5 mL) and treated with 0.5 N HCl (16 mL) for 2 hours. The organic solvent was 
evaporated under reduced pressure, the aqueous layer was brought to pH 8 by addition 
of 2 N NaOH (8 mL), and the resulting mixture was extracted with EtOAc (3×50 mL), 
dried over Na2SO4 and concentrated to dryness. Column chromatography of the residue 
on silica gel (8 g) using 80:1 CH2Cl2/MeOH as eluent yielded (±)-cis-10 (0.19 g, 80%) 
as a white solid. M.p. 162−164ºC. Rf (40:1 CHCl3/MeOH) = 0.25. IR (KBr): ν = 3373, 
3277, 1595, 1564, 1445, 1397, 1341, 1126 and 1089 cm−1. 1H NMR (300 MHz, CDCl3) 
δ: 8.74 (s, 1H, purine 8-H), 8.10 (s, 1H, purine 2-H), 7.36 (d, 1H, J = 5.0 Hz, 2-H), 6.74 
(d, 1H, J = 5.0 Hz, 3-H), 6.12 (dd, 1H, J = 8.6 and 4.1 Hz, 4-H), 3.95 and 3.77 (the AB 
part of an ABM system, 2H, JAB = 10.5, JAM = 5.4 and JBM = 4.4 Hz, OCH2), 3.66−3.59 
(m, 1H, 6-H), 3.51−3.41 (m, 1H, 5-H), 2.95 (t, 1H, J = 4.5 Hz, D2O exch., OH), 2.47 
(dt, 1H, J = 14.2 and 4.3 Hz, 5-H) ppm. 13C NMR (75 MHz, CDCl3) δ: 152.16 (purine 
C-2), 151.88 (purine C-6), 151.22 (purine C-4), 148.93 (purine C-5), 144.82 (purine C-
8), 142.35 (C-6a), 132.18 (C-3a), 131.94 (C-3), 121.26 (C-2), 65.74 (CH2O), 55.51 (C-
4), 43.79 (C-6), 41.70 (C-5) ppm. FABMS, m/z (%): 307 (15) [M+1]+, 306 (1) [M+], 
288 (11) [M+−H2O], 155 (35), 154 (100) [M+−C5HClN4], 153 (14), 137 (99) 
[M+−C5H2ClN4O], 109 (24). C13H11ClN4OS (306.03): calcd. C 50.90, H 3.61, Cl 11.56, 
N 18.26, S 10.45; found C 50.68, H 3.69, Cl 11.70, N 18.23, S 10.52. 
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3.1.3 (±)-[cis-4-(6-Amino-9H-purin-9-yl)-5,6-dihydro-4H-cyclopenta[b]thiophen-6-
yl]methanol (12). Concentrated NH4OH (40 mL) was added to a solution of (±)-cis-10 
(0.06 g, 0.196 mmol) in dioxane (5 mL) and the mixture was refluxed for 42 hours. Once 
cool, the solvents were evaporated under reduced pressure and chromatography of the 
residue on silica gel (9 g) using 20:1 CH2Cl2 as eluent yielded (±)-cis-12 (0.055 g, 98%) 
as a yellowish solid. An analytical sample was obtained by recrystallization from EtOH. 
M.p. 213−215oC. Rf (30:1 CH2Cl2/MeOH) = 0.11. IR (KBr): ν = 3097, 2923, 2821, 
1687, 1608, 1526, 1468, 1299 and 1080 cm−1. 1H NMR (300 MHz, DMSO-d6) δ: 8.14 
(s, 1H, purine 8-H), 7.85 (s, 1H, purine 2-H), 7.46 (d, 1H, J = 4.95 Hz, 2-H), 7.22 (br s, 
2H, D2O exch., NH2), 6.76 (d, 1H, J = 5.0 Hz, 3-H), 5.96 (dd, 1H, J = 8.1 and 5.7 Hz, 4-
H), 5.01 (t, 1H, J = 4.8 Hz, D2O exch., OH), 3.66−3.60 (m, 1H, OCHH), 3.54−3.47 (m, 
1H, OCHH), 3.45−3.39 (m, 1H, 6-H), 3.25−3.15 (m, 1H, 5-H), 2.33−2.24 (m, 1H, 5-H) 
ppm. 13C NMR (75 MHz, DMSO-d6) δ: 156.00 (purine C-6), 152.36 (purine C-2), 
149.36 (purine C-4), 147.47 (purine C-5), 143.03 (C-6a), 138.64 (purine C-8), 130.62 
(C-3), 120.96 (C-2), 119.01 (C-3a), 64.63 (CH2O), 53.82 (C-4), 43.29 (C-6), 40.34 (C-
5) ppm. FABMS m/z (%): 288 (19) [M+1]+, 287 (1) [M+], 155 (35) [C8H11OS]+, 154 
(95) [C8H10OS]+, 137 (100) [C8H9S]+, 135 (11) [C5H5N5]+, 109 (26), 105 (11). 
C13H13N5OS (287.08): calcd. C 54.34, H 4.56, N 24.37, S 11.16; found C 54.21, H 4.65, 
N 24.59, S 11.01. 
3.1.4 (±)-[cis-4-(6-Cyclopropylamino-9H-purin-9-yl)-5,6-dihydro-4H-cyclopen-
ta[b]thiophen-6-yl]methanol (13). A mixture of (±)-cis-10 (0.06 g, 0.20 mmol) and 
cyclopropylamine (0.14 mL, 2.02 mmol) in dry EtOH (5 mL) was refluxed under Ar for 
3 hours and then concentrated to dryness. The residue was chromatrographed on silica 
gel (9 g) using 30:1 CH2Cl2/MeOH as eluent, yielding (±)-cis-13 as a white solid 
(0.056 g, 88%). An analytical sample was obtained by recrystallization from EtOAc. 
M.p. 135−137ºC. Rf (30:1 CH2Cl2/MeOH) = 0.18. IR (KBr): ν = 3242, 1738, 1618, 
1474, 1309, 1265 and 1053 cm−1. 1H NMR (300 MHz, CDCl3) δ: 8.44 (s, 1H, purine 8-
H), 7.62 (s, 1H, purine 2-H), 7.32 (d, 1H, J = 5.0 Hz, 2-H), 6.72 (d, 1H, J = 5.0 Hz, 3-
H), 6.11 (br s, 1H, D2O exch., NH), 5.99 (dd, 1H, J = 8.6 and 4.7 Hz, 4-H), 3.94−3.89 
(m, 1H, OCHH), 3.77−3.71 (m, 1H, OCHH), 3.61−3.55 (m, 2H, one of them D2O exch., 
6-H + OH), 3.46−3.35 (m, 1H, cyclopropyl CH), 3.02−3.01 (m, 1H, 5-H), 2.49 (dt, 1H, 
J = 14.1 and 4.8 Hz, 5-H), 0.94−0.88 (m, 2H, cyclopropyl CH2), 0.66−0.60 (m, 2H, 
cyclopropyl CH2) ppm. 13C NMR (75 MHz, CDCl3) δ: 156.23 (purine C-6), 153.42 
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(purine C-2), 149.18 (purine C-4), 148.12 (purine C-5), 143.21 (C-6a) 138.97 (purine C-
8), 131.46 (C-3), 121.44 (C-2), 120.87 (C-3a), 66.10 (CH2O), 55.26 (C-4), 43.90 (C-6), 
41.45 (C-5), 30.05 (cyclopropyl CH2), 24.67 (cyclopropyl CH), 7.79 (cyclopropyl CH2) 
ppm. FABMS m/z (%): 328 (50) [M+1]+, 327 (4) [M+], 309 (23), 278 (27), 263 (15), 
231 (68), 176 (16) [C8H10N5]+, 156 (11), 155 (37) [C8H11OS]+, 154 (98) [C8H10OS], 137 
(100) [C8H9S], 135 (10) [C5H5N5], 109 (23), 105 (10). C16H17N5OS (327.12): calcd. C 
58.70, H 5.23, N 21.39, S 9.79; found C 58.51, H 5.36, N 21.48, S 9.98. 
3.1.5. (±)-6,9-Dihydro-9-[cis-(6-hydroxymethyl)-5,6-dihydro-4H-cyclopenta[b]thio-
phen-4-yl)]-1H-purin-6-one (14). 0.25 N NaOH (8 mL) was added to a solution of (±)-
cis-10 (0.1 g, 0.33 mmol) in dioxane (15 mL). The mixture was heated at 50oC for 24 h 
and then cooled, the solvents were removed under reduced pressure, and the solid 
residue (0.23 g) was purified by column chromatography on silica gel (10 g) using 30:1 
CH2Cl2/MeOH as eluent. From the non-void fractions, (±)-cis-14 (0.055 g, 59%) was 
obtained as a white solid. M.p. 219−221ºC. Rf (20:1 CH2Cl2/MeOH) = 0.08. IR (KBr): ν  
= 3108, 2923, 2875, 1705, 1607, 1584, 1506, 1348, 1206, 1137 and 1039 cm−1. 1H 
NMR (300 MHz, DMSO-d6) δ: 12.30 (br s, 1H, D2O exch., purine OH), 8.05 (s, 1H, 
purine 8-H), 7.80 (s, 1H, purine 2-H), 7.47 (d, 1H, J = 5.0 Hz, 2-H), 6.77 (d, 1H, J = 5.0 
Hz, 3-H), 5.95 (dd, 1H, J = 8.1 and 5.7 Hz, 4-H), 5.01 (t, 1H, J = 4.9 Hz, D2O exch., 
CH2OH), 3.66−3.59 (m, 1H, 6-H), 3.53−3.36 (m, 2H, OCH2), 3.25−3.15 (m, 1H, 5-H), 
2.27 (dt, 1H, J = 13.6 and 5.6 Hz, 5-H) ppm. 13C NMR (75 MHz, DMSO-d6) δ: 157.21 
(purine C-6), 148.54 (purine C-4), 148.10 (purine C-5), 145.89 (purine C-2), 142.88 (C-
6a), 138.43 (purine C-8), 131.10 (C-3), 124.75 (C-3a), 121.29 (C-2), 64.93 (CH2O), 
54.65 (C-4), 43.64 (C-6), 40.96 (C-5) ppm. FABMS m/z (%): 289 (35) [M+1]+, 288 (3) 
[M+], 262 (11), 231 (53), 156 (10), 155 (32), [C8H11OS]+, 154 (90) [C8H10OS]+, 137 
(100) [C8H9S]+, 135 (13) [C5H3N4O]+, 109 (32), 105 (13). C13H12N4O2S (288.07): calcd. 
C 54.15, H 4.20, N 19.43, S 11.12; found C 54.25, H 4.31, N 19.24, S 11.08. 
3.1.6 (±)-[cis-4-(6-Phenyl-9H-purin-9-yl)-5,6-dihydro-4H-cyclopenta[b]thiophen-6-
yl]methanol (15). A mixture of (±)-cis-10 (0.068 g, 0.22 mmol), phenylboronic acid 
(0.041 g, 0.33 mmol), Pd(PPh3)4 (0.012 g, 0.011 mmol) and K2CO3 (0.046 g, 0.33 
mmol) in dry toluene (10 mL) was stirred under Ar at 100oC for 48 hours, after which it 
was allowed to reach room temperature and the solvent was removed under reduced 
pressure. The solid residue was chromatographed on silica gel (13 g) using 2:1 
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hexane/EtOAc as eluent, and the product obtained from the non-void fractions after 
removal of the solvent was washed with diethyl ether, yielding (±)-cis-15 (0.047 g, 
61%) as a white solid. M.p. 138−140ºC. Rf (1:1 hexane/EtOAc) = 0.38. IR (KBr): ν = 
3322, 2925, 1683, 1566, 1438, 1317, 1208 and 1026 cm−1. 1H NMR (300 MHz, CDCl3) 
δ: 9.01 (s, 1H, purine 8-H), 8.77 (dd, 2H, J = 7.9 and 1.7 Hz, 2’ + 6’-Harom), 8.07 (s, 1H, 
purine 2-H), 7.59−7.52 (m, 3H, 3’ + 4’ + 5’-Harom), 7.37 (d, 1H, J = 5.1 Hz, 2-H), 6.78 
(d, 1H, J = 5.0 Hz, 3-H), 6.18 (dd, 1H, J = 8.5 and 4.7 Hz, 4-H), 3.97 and 3.77 (the AB 
part of an ABM system, 2H, JAB = 10.4, JAM = 5.3 and JBM = 4.7 Hz, OCH2), 3.67−3.61 
(m, 1H, 6-H), 3.53−3.42 (m, 1H, 5-H), 2.51 (dt, 1H, J = 14.1 and 4.8 Hz, 5-H), 
2.42−2.35 (m, 1H, D2O exch., OH) ppm. 13C NMR (75 MHz, CDCl3) δ: 155.88 (purine 
C-6), 152.56 (purine C-2), 148.23 (purine C-4), 143.56 (C-6a), 142.94 (purine C-8), 
136.04 (purine C-5), 132.01 (C-1’arom), 131.74 (CHarom), 131.40 (C-3), 130.19 and 
129.08 (4 × CHarom), 121.41 (C-2), 120.93 (C-3a), 66.15 (CH2O), 55.20 (C-4), 43.83 (C-
6), 41.50 (C-5) ppm. FABMS m/z (%): 349 (19) [M+1]+, 348 (1) [M+], 309 (17), 278 
(26), 263 (16), 231 (74), 197 (17) [C11H9N4]+, 156 (11), 155 (36) [C8H11OS]+, 154 (94) 
[C8H10OS]+, 137 (100) [C8H9S]+, 109 (26), 105 (12). C19H16N4OS (348.10): calcd. C 
65.50, H 4.63, N 16.08, S 9.20; found C 65.34, H 4.78, N 15.91, S 9.44. 
3.1.7 (±)-[trans-4-(6-Chloro-9H-purin-9-yl)-5,6-dihydro-4H-cyclopenta[b]thiophen-
6-yl]methanol (11). A mixture of (±)-trans-9 (0.2 g, 0.68 mmol), triethyl orthoformiate 
(3.8 mL, 33.8 mmol), dioxane (10 mL) and 12 N HCl (0.23 mL) was stirred at room 
temperature for 3.5 hours. Once the reaction was judged to have terminated, the mixture 
was concentrated to dryness under reduced pressure, and the residue was dissolved in 
dioxane (10 mL) and treated for 1.5 h with 0.5 N HCl (14 mL). (±)-trans-11 was 
obtained as a white solid (0.18 g, 87%) in the same way as (±)-cis-10. An analytical 
sample was obtained by recrystallization from EtOAc. M.p. 134−136ºC. Rf (40:1 
CHCl3/MeOH) = 0.24. IR (KBr): ν = 3372, 2926, 1590, 1560, 1485, 1395, 1334, 1202 
and 1042 cm−1. 1H NMR (300 MHz, CDCl3) δ: 8.75 (s, 1H, purine 8-H), 7.82 (s, 1H, 
purine 2-H), 7.37 (d, 1H, J = 5.0 Hz, 2-H), 6.82 (d, 1H, J = 5.0 Hz, 3-H), 6.17 (dd, 1H, J 
= 7.9 and 2.4 Hz, 4-H), 3.93−3.89 (m, 1H, OCHH), 3.79−3.72 (m, 2H, OCHH + 6-H), 
3.05−2.96 (m, 1H, 5-H), 2.75−2.67 (m, 1H, 5-H), 2.28 (br s, 1H, D2O exch., OH) ppm. 
13C NMR (75 MHz, CDCl3) δ: 152.30 (purine C-2), 151.90 (purine C-6), 151.45 (purine 
C-4), 149.14 (purine C-5), 143.78 (purine C-8), 142.19 (C-6a), 132.43 (C-3a), 131.91 
(C-3), 121.36 (C-2), 66.22 (CH2O), 55.82 (C-4), 43.84 (C-6), 42.44 (C-5) ppm. FABMS 
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m/z (%): 307 (61) [M+1]+, 306 (2) [M+], 288 (2) [M+−H2O], 155 (51), 154 (100) 
[M+−C5HClN4], 153 (45), 137 (91) [M+−C5H2ClN4O], 109 (25). C13H11ClN4OS 
(306.03): calcd. C 50.90, H 3.61, Cl 11.56, N 18.26, S 10.45; found C 50.72, H 3.57, Cl 
11.74, N 18.18, S 10.54. 
3.1.8 (±)-[trans-4-(6-Amino-9H-purin-9-yl)-5,6-dihydro-4H-cyclopenta[b]thiophen-
6-yl]methanol (16). Concentrated NH4OH (22 mL) was added to a solution of (±)-
trans-11 (0.07 g, 0.23 mmol) in dioxane (5 mL), and the mixture was refluxed for 23 
hours. (±)-trans-16 (0.055 g, 85%) was obtained as a beige solid by a procedure similar 
to that used for (±)-cis-12. M.p. 100−102oC. Rf (20:1 CH2Cl2/MeOH) = 0.22. IR (KBr): 
ν = 3319, 3172, 2923, 2854, 1646, 1579, 1471, 1409, 1369, 1329, 1299, 1207 and 1037 
cm−1. 1H NMR (300 MHz, DMSO-d6) δ: 8.14 (s, 1H, purine 8-H), 7.83 (s, 1H, purine 2-
H), 7.43 (d, 1H, J = 4.9 Hz, 2-H), 7.20 (br s, 2H, D2O exch., NH2), 6.81 (d, 1H, J = 5.0 
Hz, 3-H), 5.98−5.95 (m, 1H, 4-H), 5.03 (t, 1H, J = 4.7 Hz, D2O exch., OH), 3.75−3.61 
(m, 2H, OCH2), 3.50−3.41 (m, 1H, 6-H), 2.80−2.66 (m, 2H, 5-H) ppm. 13C NMR (75 
MHz, DMSO-d6) δ: 157.01 (purine C-6), 152.79 (purine C-2), 149.88 (purine C-4), 
148.01 (purine C-5), 144.06 (C-6a), 139.07 (purine C-8), 130.84 (C-3), 121.38 (C-2), 
118.93 (C-3a), 65.07 (CH2O), 54.32 (C-4), 43.78 (C-6), 41.02 (C-5) ppm. FABMS m/z 
(%): 288 (12) [M+1]+, 287 (1) [M+], 155 (36) [C8H11OS]+, 154 (100) [C8H10OS]+, 137 
(99) [C8H9S]+, 135 (10) [C5H5N5]+, 109 (22), 105 (10). C13H13N5O5 (287.08): calcd. C 
54.34, H 4.56, N 24.37, S 11.16; found C 54.40, H 4.62, N 24.17, S 11.08. 
3.1.9 (±)-[trans-4-(6-Cyclopropylamino-9H-purin-9-yl)-5,6-dihydro-4H-cyclopen-
ta[b]thiophen-6-yl]methanol (17). A solution of (±)-trans-11 (0.084 g, 0.27 mmol) and 
cyclopropylamine (0.2 mL, 2.89 mmol) in dry EtOH (7 mL) was refluxed under Ar for 
6 hours. (±)-trans-17 (0.056 g, 73%) was obtained as a white solid by a method similar 
to that used for (±)-cis-13. An analytical sample was obtained by recrystallization from 
1:1 hexane/EtOAc. M.p. 73−75oC. Rf (30:1 CH2Cl2/MeOH) = 0.16. IR (KBr): ν = 3256, 
2923, 1619, 1469, 1354, 1314, 1297, 1220 and 1042 cm−1. 1H NMR (300 MHz, CDCl3) 
δ: 8.48 (s, 1H, purine 8-H), 7.39 (s, 1H, purine 2-H), 7.32 (d, 1H, J = 4.9 Hz, 2-H), 6.81 
(d, 1H, J = 4.9 Hz, 3-H), 6.31 (br s, 1H, D2O exch., NH), 6.07 (dd, 1H, J = 7.5 and 2.6 
Hz, 4-H), 3.91−3.84 (m, 1H, OCHH), 3.73−3.69 (m, 2H, OCHH + 6-H), 3.02−2.82 (m, 
3H, one of them D2O exch., OH + 5-H + cyclopropyl CH), 2.69−2.62 (m, 1H, 5-H), 
1.05−0.84 (m, 2H, cyclopropyl CH2), 0.66−0.60 (m, 2H, cyclopropyl CH2) ppm. 13C 
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NMR (75 MHz, CDCl3) δ: 156.20 (purine C-6), 153.59 (purine C-2), 148.95 (purine C-
4), 148.84 (purine C-5), 142.90 (C-6a), 138.25 (purine C-8), 131.35 (C-3), 121.63 (C-
2), 120.48 (C-3a), 66.15 (CH2O), 54.90 (C-4), 43.85 (C-6), 42.73 (C-5), 24.10 
(cyclopropyl CH), 7.77 (2 × cyclopropyl CH2) ppm. FABMS m/z (%): 328 (25) [M+1]+, 
327 (2) [M+], 309 (16), 278 (16), 263 (12), 231 (59), 176 (11) [C8H10N5]+, 156 (10), 155 
(33) [C8H11OS]+, 154 (100) [C8H10OS]+, 137 (98) [C8H9S]+, 135 (10) [C5H5N5]+, 109 
(23), 105 (9). C16H17N5OS (327.12): calcd. C 58.70, H 5.23, N 21.39, S 9.79; found C 
58.77, H 5.42, N 21.32, S 9.68. 
3.1.10. (±)-6,9-Dihydro-9-[trans-(6-hydroxymethyl-5,6-dihydro-4H-cyclopen-
ta[b]thiophen-4-yl)]-1H-purin-6-one (18). 0.25 N NaOH (7 mL) was added to a 
solution of (±)-trans-11 (0.1 g, 0.33 mmol) in dioxane (15 mL), and the mixture was 
heated at 50oC for 24 hours. (±)-trans-18 (0.049 g, 52%) was isolated as a white solid 
following a procedure similar to that used for (±)-cis-14. An analytical sample was 
obtained by recrystallization from 9:1 EtOAc/MeOH. M.p. 225−227oC. Rf (20:1 
CH2Cl2/MeOH) = 0.10. IR (KBr): ν = 3747, 3662, 2923, 1857, 1694, 1581, 1543, 1459, 
1206, 1099 and 1039 cm−1. 1H NMR (300 MHz, DMSO-d6) δ: 12.29 (br s, 1H, D2O 
exch., purine OH), 8.03 (s, 1H, purine 8-H), 7.78 (s, 1H, purine 2-H), 7.44 (d, 1H, J = 
4.9 Hz, 2-H), 6.81 (d, 1H, J = 5.0 Hz, 3-H), 5.96 (dd, 1H, J = 7.3 and 3.2 Hz, 4-H), 5.03 
(t, 1H, J = 4.5 Hz, D2O exch., CH2OH), 3.73−3.60 (m, 2H, OCH2), 3.45−3.37 (m, 1H, 
6-H), 2.81−2.66 (m, 2H, 5-H) ppm. 13C NMR (75 MHz, DMSO-d6) δ: 156.88 (purine 
C-6), 148.43 (purine C-4), 148.22 (purine C-5), 145.85 (purine C-2), 143.86 (C-6a), 
138.55 (purine C-8), 130.96 (C-3), 124.78 (C-3a), 121.31 (C-2), 65.02 (CH2O), 54.81 
(C-4), 43.72 (C-6), 41.07 (C-5) ppm. FABMS m/z (%): 289 (5) [M+1]+, 288 (5) [M+], 
263 (13), 231 (65), 156 (10), 155 (37) [C8H11OS]+, 154 (81) [C8H10OS]+, 137 (100) 
[C8H9S]+, 135 (11) [C5H3N4O]+, 110 (11), 109 (25), 105 (11). C13H12N4O2S (288.07): 
calcd. C 54.15, H 4.20, N 19.43, S 11.12; found C 53.97, H 4.28, N 19.31, S 11.30. 
3.1.11 (±)-[trans-4-(6-Phenyl-9H-purin-9-yl)-5,6-dihydro-4H-cyclopenta[b]thio-
phen-6-yl]methanol (19). A mixture of (±)-trans-11 (0.125 g, 0.41 mmol), 
phenylboronic acid (0.075 g, 0.62 mmol), Pd(PPh3)4 (0.023 g, 0.02 mmol) and K2CO3 
(0.086 g, 0.62 mmol) in dry toluene (17 mL) was stirred under Ar at 100oC for 38 hours. 
(±)-trans-19 (0.11 g, 77%) was isolated as a white solid by a procedure similar to that 
used for (±)-cis-15. M.p. 166−168oC. Rf (1:1 hexane/EtOAc) = 0.21. IR (KBr): ν = 
3321, 2916, 1567, 1496, 1407, 1323, 1206, 1127 and 1024 cm−1. 1H NMR (300 MHz, 
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DMSO-d6) δ: 8.99 (s, 1H, purine 8-H), 8.83−8.81 (m, 2H, 2’ + 6’-Harom), 8.42 (s, 1H, 
purine 2-H), 7.59−7.57 (m, 3H, 3’ + 4’ + 5’-Harom), 7.44 (d, 1H, J = 4.9 Hz, 2-H), 6.85 
(d, 1H, J = 4.9 Hz, 3-H), 6.20−6.17 (m, 1H, 4-H), 5.07 (t, 1H, J = 4.9 Hz, D2O exch., 
OH), 3.81−3.79 (m, 1H, OCHH), 3.70−3.66 (m, 1H, OCHH), 3.50−3.45 (m, 1H, 6-H), 
2.85−2.81 (m, 2H, 5-H) ppm. 13C NMR (75 MHz, DMSO-d6) δ: 153.02 (purine C-6), 
152.40 (purine C-4), 152.11 (purine C-2), 149.07 (C-6a), 145.02 (purine C-8), 143.16 
(purine C-5), 135.80 (C-1’arom), 131.37 (C-3), 131.13 (CHarom), 131.00 (C-3a), 129.70 
and 129.01 (4 × CHarom), 121.39 (C-2), 65.07 (CH2O), 54.89 (C-4), 43.89 (C-6), 40.79 
(C-5) ppm. FABMS m/z (%): 349 (40) [M+1]+, 348 (1) [M+], 309 (13), 278 (17), 263 
(13), 231 (68), 197 (37) [C11H9N4]+, 156 (9), 155 (27) [C8H11OS]+, 154 (89) 
[C8H10OS]+, 137 (100) [C8H9S]+, 109 (30), 105 (12). C19H16N4OS (348.10): calcd. C 
65.50, H 4.63, N 16.08, S 9.20; found C 65.28, H 4.81, N 16.18, S 9.31. 
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